Wegovy Pill Shakes GLP-1 Market: Eli Lilly Still Has Edge
💡 Key Takeaway
Oral Wegovy's strong launch challenges Eli Lilly, but Zepbound and a deep pipeline keep LLY a long-term winner.
What Happened: Oral Wegovy Dominates, But Eli Lilly Fights Back
Novo Nordisk launched oral Wegovy in the U.S. in January, and it has been a massive success. By June, it crossed three million prescriptions, making it one of the strongest pharmaceutical launches on record by volume. More than 80% of new prescriptions are for patients who had never taken GLP-1 medicines before, meaning the drug is expanding the market rather than just cannibalizing existing products.
Oral Wegovy now accounts for about 89% of oral weight-loss medication prescriptions in the U.S., far ahead of Eli Lilly's competing oral drug, Foundayo. The success is attributed to Wegovy's strong brand recognition, physician familiarity with semaglutide, and better efficacy in phase 3 studies.
Eli Lilly's Foundayo, approved in April, has some advantages: it can be taken any time without food or water restrictions, while oral Wegovy must be taken on an empty stomach. Foundayo is also undergoing clinical trials for multiple other indications, including diabetes, sleep apnea, and hypertension, which could expand its eligible patient population.
Despite the oral market challenge, Eli Lilly remains the overall leader in weight-loss drugs thanks to Zepbound, which has become the best-selling anti-obesity drug since its approval in November 2023. The company also has promising pipeline candidates like retatrutide, whose phase 3 results have been compared to bariatric surgery outcomes.
Why It Matters: GLP-1 Market Share Battle and Investment Implications
The GLP-1 market is one of the fastest-growing in pharma, and the battle between Novo Nordisk and Eli Lilly is critical for investors. Oral Wegovy's success shows that Novo Nordisk can still innovate and capture market share, even as Eli Lilly leads overall. This dynamic affects both stocks' growth trajectories.
For Eli Lilly, the oral market loss is a near-term headwind, but its strength in injectables (Zepbound) and a deep pipeline provide a buffer. Foundayo's potential label expansions could unlock a much larger patient pool, especially for comorbidities common in overweight patients.
Novo Nordisk's oral Wegovy success demonstrates its ability to defend its turf, but the company still trails in overall GLP-1 sales. Its pipeline, including UBT251 and denecimig, offers diversification beyond weight loss.
Investors should watch prescription trends, label expansions, and pipeline progress. Both companies have strong fundamentals, but Eli Lilly's broader portfolio and pipeline give it an edge in long-term growth potential.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Eli Lilly is the better long-term buy due to its dominant Zepbound franchise and promising pipeline.
While oral Wegovy is impressive, Eli Lilly's Zepbound remains the top-selling anti-obesity drug, and its pipeline includes retatrutide with bariatric surgery-level efficacy. Foundayo's label expansions could also drive future growth. Novo Nordisk is a strong competitor, but Eli Lilly's broader portfolio and innovation pipeline give it a clearer path to sustained leadership.
What This Means for Me
